Volume 24, Issue 3 (Jun 2016)                   JSSU 2016, 24(3): 251-260 | Back to browse issues page

XML Persian Abstract Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Naeimi S. TGF-β1 Gene Polymorphism at Position -800G /A and Systemic Lupus Erythematosus. JSSU 2016; 24 (3) :251-260
URL: http://jssu.ssu.ac.ir/article-1-3626-en.html
Abstract:   (5704 Views)

Introduction: Systemic lupus erythematosus (SLE) is a chronic systemic inflammatory autoimmune disease characterized by a breakdown of self-tolerance. Transforming growth factor-β1 is a cytokine produced by both immune and non immune cells, and it has a wide operating range. human TGF-β1 gene is located on chromosome 19q13 . The aim of this study was investigating the TGF-β1 Gene Polymorphism at Position -800G /A and Systemic Lupus Erythematosus the possible difference in two promoter polymorphisms of the transforming growth factor-β1 (TGF-β1) gene (-800G / A, -509C / T).

Methods: In this case - control study, a total of 150 patients with SLE and 150 healthy subjects were examined. DNA was extracted by saluting out method and Single nucleotide Polymorphisms of the TGF-β1gene were analyzed by the PCR-RFLP method and the .Data were compared in both groups by using Pearson’s chi-square and Hardy-weinberg equilibrium test.

Results: There was a statistically significant difference in AA genotype and A allele frequency distributions between SLE patients and the control group for the -800G / A polymorphism of the TGF-β1 gene (P < 0.05). At position -509, there was no statically significant difference in genotype and allele frequency between the patients and the control subjects.

Conclusion : The results of our study indicate that TGF-β1 gene promoter polymorphisms at positions -800 G/A maybe discuss susceptibility to SLE in southern Iranian patients.

Full-Text [PDF 421 kb]   (1658 Downloads)    
Type of Study: Original article | Subject: Immunology
Received: 2016/02/20 | Accepted: 2016/06/5 | Published: 2016/08/9

1. Devarajan P, Chen Z. Autoimmune effector memory T cells: the bad and the good. Immunologic Res 2013; 57(1-3): 12-22.
2. Anaya JM. The autoimmune tautology. Arthritis Res Therapy 2010; 12(6): 1.
3. Patterson CC, Dahlquist GG, Gyürüs E, Green A, Soltész G, Group ES. Incidence trends for childhood type 1 diabetes in Europe during 1989–2003 and predicted new cases 2005–20: a multicentre prospective registration study. Lancet 2009; 373(9680): 2027-33.
4. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Seminars in arthritis and rheumatism 2010; Elsevier.
5. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Med 2003; 82(5): 299-308.
6. Reeves WH. Editorial: systemic lupus erythematosus: death by fire and ICE? Arthritis & Rheumato 2014; 66(1): 6-9.
7. Nasonov E, Soloviev S, Davidson JE, Lila A, Togizbayev G, Ivanova R, et al. Standard medical care of patients with systemic lupus erythematosus (SLE) in large specialised centres: data from the Russian Federation, Ukraine and Republic of Kazakhstan (ESSENCE). Lupus Sci Med 2015; 19; 2(1).
8. Adelowo OO, Bello MKN. Systemic Autoimmune Diseases: Not So Rare in Black Africans. Rheumato 2014; (Sunnyvale) 4: 130.
9. Yap DYH, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. BioMed Res Inter 2010.
10. Eskdale J, Gallagher G, Verweij CL, Keijsers V, Westendorp RG, Huizinga TW. Interleukin 10 secretion in relation to human IL-10 locus haplotypes. Proceedings National Academy Sci United States America 1998; 4; 95(16): 9465-70.
11. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. Transforming growth factor-beta regulation of immune responses. Annual Rev immuno 2006; 24: 99-146.
12. Moustakas A, Pardali K, Gaal A, Heldin CH. Mechanisms of TGF-beta signaling in regulation of cell growth and differentiation. Immuno letters 2002; 82(1): 85-91.
13. Sonmezer M, Gungor M, Ensari A, Ortac F. Prognostic significance of tumor angiogenesis in epithelial ovarian cancer: in association with transforming growth factor beta and vascular endothelial growth factor. Inter J gynecological cancer 2004; 14(1): 82-8.
14. Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol 2001; 112(1): 146-52.
15. Emigh TH. A comparison of tests for Hardy-Weinberg equilibrium. Biometrics 1980; 36(4): 627-42.
16. Mok CC, Lau CS. Pathogenesis of systemic lupus erythematosus. J Clinic patho 2003; 56(7): 481-90.
17. Nagy G, Huszthy PC, Fossum E, Konttinen Y, Nakken B, Szodoray P. Selected Aspects in the Pathogenesis of Autoimmune Diseases. Mediators of Inflammation 2015; 501: 351732.
18. Crispín JC, Liossis SNC, Kis-Toth K, Lieberman LA, Kyttaris VC, Juang YT, et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends in molecular Med 2010; 16(2): 47-57.
19. Apostolidis SA, Lieberman LA, Kis-Toth K, Crispin JC, Tsokos GC. The dysregulation of cytokine networks in systemic lupus erythematosus. J Interferon Cytokine Res 2011; 31(10): 769-79.
20. Grainger DJ, Mosedale DE, Metcalfe JC. TGF-beta in blood: a complex problem. Cytokine & growth factor Rev 2000; 11(1): 133-45.
21. Grainger DJ, Heathcote K, Chiano M, Snieder H, Kemp PR, Metcalfe JC, et al. Genetic control of the circulating concentration of transforming growth factor type beta1. Human molecular genetics 1999; 8(1):93-7.
22. Jin T, Almehed K Fau - Carlsten H, Carlsten H Fau - Forsblad-d'Elia H, Forsblad-d'Elia H. Decreased serum levels of TGF-beta1 are associated with renal damage in female patients with systemic lupus erythematosus. Lupus 2012; 21(3): 310-18.
23. Talaat RM, Mohamed SF, Bassyouni IH, Raouf AA. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity. Cytokine 2015; 72(2): 146-53.
24. Elbeldi-Ferchiou A, Ben Ahmed M, Smiti-Khanfir M, Houman MH, Abdeladhim M, Belhadj Hmida N, Cerf-Bensussan N, Louzir H. Resistance to exogenous TGF-beta effects in patients with systemic lupus erythematosus. J Clin Immunol 2011; 31(4): 574-83.
25. Zhang L, Yan JW, Wang YX, Wan YN, Li JP, Liu P, et al . Association of TGF-beta1 +869C/T promoter polymorphism with susceptibility to autoimmune diseases: a meta-analysis. Mol Biol Rep 2013; 40(8): 4811-17.

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 CC BY-NC 4.0 | SSU_Journals

Designed & Developed by : Yektaweb